

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner
 US Department of Commerce
 United States Patent and Trademark
 Office, PCT
 2011 South Clark Place Room
 CP2/5C24
 Arlington, VA 22202
 ETATS-UNIS D'AMERIQUE
 in its capacity as elected Office

Date of mailing (day/month/year) 12 June 2001 (12.06.01)	
International application No. PCT/KR99/00554	Applicant's or agent's file reference P9929/MBRI
International filing date (day/month/year) 15 September 1999 (15.09.99)	Priority date (day/month/year)
Applicant CHANG, Jihoon et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:
 16 April 2001 (16.04.01)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Zakaria EL KHODARY
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

COPY FOR IB

PATENT COOPERATION TREATY

PCT

REC'D 30 JAN 2002

WIPO PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT


(PCT Article 36 and Rule 70)

Applicant's or agent's file reference P9929/MBRI	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/KR99/00554	International filing date (day/month/year) 15 SEPTEMBER 1999 (15.09.1999)	Priority date (day/month/year)
International Patent Classification (IPC) or national classification and IPC IPC7 C07K 14/47, C12N 15/63, C12N 15/70, C12N 1/21, A61K 38/17		
Applicant MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE et al		

- This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
- This REPORT consists of a total of 4 sheets, including this cover sheet.
☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).
These annexes consist of a total of _____ sheets.

- This report contains indications relating to the following items:
 - I ☒ Basis of the report
 - II ☐ Priority
 - III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
 - IV ☐ Lack of unity of invention
 - V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
 - VI ☐ Certain documents cited
 - VII ☐ Certain defects in the international application
 - VIII ☐ Certain observations on the international application

Date of submission of the demand 16 APRIL 2001 (16.04.2001)	Date of completion of this report 18 JANUARY 2002 (18.01.2002)
Name and mailing address of the IPEA/KR Korean Intellectual Property Office Government Complex-Daejeon, Dunsan-dong, Seo-gu, Daejeon Metropolitan City 302-701, Republic of Korea Facsimile No. 82-42-472-7140	Authorized officer HAN, Hyun Sook Telephone No. 82-42-481-5596



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/KR99/00554

1. Basis of the report

1. With regard to the elements of the international application:*

☒ the international application as originally filed

☐ the description:

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

_____ , as originally filed
_____ , filed with the demand

_____ , filed with the letter of _____

☐ the claims:

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

_____ , as originally filed

_____ , as amended (together with any statement) under Article 19

_____ , filed with the demand

_____ , filed with the letter of _____

☐ the drawings:

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

_____ , as originally filed

_____ , filed with the demand

_____ , filed with the letter of _____

☐ the sequence listing part of the description:

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

pages _____

_____ , as originally filed

_____ , filed with the demand

_____ , filed with the letter of _____

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language English which is

☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).

☒ the language of publication of the international application (under Rule 48.3(b)).

☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form

☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☐ The amendments have resulted in the cancellation of:

☐ the description, pages _____

☐ the claims, Nos. _____

☐ the drawings, sheet _____

5. ☐ This opinion has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed." and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/KR99/00554

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application,

☒ claims Nos. 18 and 19

because:

☒ the said international application, or the said claims Nos. 18 and 19

relate to the following subject matter which does not require an international preliminary examination (*specify*):

The subject-matter of claims 18 and 19 does not require an international preliminary examination, as it relates to a method of treatment of the human or animal body by therapy(Rule 67.1(iv)).

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. _____ are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. _____ are so inadequately supported by the description that no meaningful opinion could be formed.

☐ no international search report has been established for said claims Nos. _____

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/KR99/00554

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims	1 - 17	YES
	Claims	NONE	NO
Inventive step (IS)	Claims	1 - 17	YES
	Claims	NONE	NO
Industrial applicability (IA)	Claims	1 - 17	YES
	Claims	NONE	NO

2. Citations and explanations (Rule 70.7)

Claims 1-17 meet the requirements of novelty, inventive step and industrial applicability under PCT Rule 33(2)-(4) since none of the citations show that the polypeptides consisting of an amino acid sequence of human apolipoprotein(a) kringle domains IV36 or IV37 or V38 exhibit inhibitory activities on the cultured endothelial cell proliferation as well as on the endothelial cell migration.

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 March 2001 (22.03.2001)

PCT

(10) International Publication Number
WO 01/19868 A1

(51) International Patent Classification⁷: C07K 14/47,
C12N 15/63, 15/70, 1/21, A61K 38/17

463-010 (KR). CHUNG, Soo-il [KR/KR]; 112-902,
Hyundae Apt., Hyoja-chon, Seohyun-dong, Pundang-ku,
Sungnam-si, Kyonggi-do 463-480 (KR).

(21) International Application Number: PCT/KR99/00554

(74) Agent: LEE, Han-Young; Seowon Building, 8th floor,
1675-1, Seocho-dong, Seocho-gu, Seoul 137-070 (KR).

(22) International Filing Date:
15 September 1999 (15.09.1999)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant (for all designated States except US): MOGAM
BIOTECHNOLOGY RESEARCH INSTITUTE
[KR/KR]; 341, Pojung-ri, Koosung-myon, Yongin-si,
Kyonggi-do 449-910 (KR).

(81) Designated States (national): AE, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE,
ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,
MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD,
SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ,
VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CHANG, Jihoon
[KR/KR]; 553-517, Jayang 3-dong, Kwangjin-ku, Seoul
143-193 (KR). KIM, Jang, Seong [KR/KR]; 902 Ikjoo
Apt., Yeonmoo-dong, JangAn-ku, Suwon-si, Kyonggi-do
440-240 (KR). PARK, Eun, Jeong [KR/KR]; 322-1007,
Woosung Apt., Sangrok-maeul, Jungja-dong, Pundang-ku,
Sungnam-si, Kyonggi-do 464-010 (KR). YUM, Jung-
sun [KR/KR]; 115-502, Chunggu Apt., Hansol-maeul,
Jungja-dong, Pundang-ku, Sungnam-si, Kyonggi-di

Published:

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.



WO 01/19868 A1

(54) Title: A NOVEL ANGIOGENESIS INHIBITOR

(57) Abstract: The present invention provides a novel angiogenesis inhibitor, LK68 whose amino acid sequence is identical with the human apolipoprotein (a) kringle domains IV36, IV37 and V38, a cDNA sequence encoding the LK68, a recombinant expression vector comprising the cDNA, a recombinant microorganism transformed with the recombinant expression vector and a novel use of the LK68 as an anticancer agent and a method for treating angiogenesis-mediated disease. LK68, LK6, LK7 and LK8 exhibit inhibitory activities on the cultured endothelial cell proliferation as well as on the endothelial cell migration. LK68 and its single kringles also inhibit the normal development of capillaries in the chick embryo chorioallantoic membrane (CAM). It was also showed that systemic administration of LK68 causes the inhibition of primary tumor growth, which is correlated with a suppression of tumor-induced angiogenesis. Accordingly, LK68 protein, its single kringles or their functional equivalents may be applied for the development of a potent anti-cancer agent, which is highly effective for angiogenesis-mediated diseases covering cancer, rheumatoid arthritis, psoriasis, ocular angiogenic disease, etc.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/KR 99/00554

CLASSIFICATION OF SUBJECT MATTER

IPC⁷: C 07 K 14/47; C 12 N 15/63, 15/70, 1/21; A 61 K 38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁷: C 07 K 14/00; C 12 N; A 61 K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CA Database, STN International, Karlsruhe (DE), Registry Database, STN International, Karlsruhe (DE), WPI Database, Derwent Publications Ltd., London (GB)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	LOGRASSO et al. "Cloning, Expression, and Characterization of Human Apolipoprotein (a) Kringle IV37", The Journal of Biological Chemistry, Vol.269, No.34, August 1994, pages 21820-21827, totality.	1-19
A	SCANU et al. "Apolipoprotein (a): Structural and Functional Consequences of Mutations in Kringle Type 10 (or Kringle 4-37)", Clinical Genetics, Vol.46, 1994, pages 42-45, totality.	1-19
A	SCANU et al. "A Single Point Mutation (Trp72=> Arg) in Human apo(a) Kringle 4-37 Associated with a Lysine Binding Defect in Lp(a)", Biochimica et Biophysica Acta, Vol 1227, 1994, pages 41-45, totality.	1-19
A	GABEL et al. "Sequences within Apolipoprotein(a) Kringle IV Types 6-8 Bind Directly to Low-Density Lipoprotein and Mediate Noncovalent Association of Apolipoprotein(a) with Apolipoprotein B-100", Biochemistry, Vol.37, 1998, pages 7892-7898, totality.	1-19

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

- „A“ document defining the general state of the art which is not considered to be of particular relevance
- „E“ earlier application or patent but published on or after the international filing date
- „L“ document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- „O“ document referring to an oral disclosure, use, exhibition or other means
- „P“ document published prior to the international filing date but later than the priority date claimed

- „T“ later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- „X“ document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- „Y“ document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- „&“ document member of the same patent family

Date of the actual completion of the international search

5 May 2000 (05.05.2000)

Date of mailing of the international search report

2 August 2000 (02.08.2000)

Name and mailing address of the ISA/AT

Austrian Patent Office
Kohlmarkt 8-10; A-1014 Vienna
Facsimile No. 1/53424/535

Authorized officer

Weniger

Telephone No. 1/53424/

INTERNATIONAL SEARCH REPORT

International application No.
PCT/KR 99/00554

CLASSIFICATION OF SUBJECT MATTER		
IPC ⁷ : C 07 K 14/47; C 12 N 15/63, 15/70, 1/21; A 61 K 38/17		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
IPC ⁷ : C 07 K 14/00; C 12 N; A 61 K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
CA Database, STN International, Karlsruhe (DE), Registry Database, STN International, Karlsruhe (DE), WPI Database, Derwent Publications Ltd., London (GB)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	LOGRASSO et al. "Cloning, Expression, and Characterization of Human Apolipoprotein (a) Kringle IV37", The Journal of Biological Chemistry, Vol.269, No.34, August 1994, pages 21820-21827, totality.	1-19
A	SCANU et al. "Apolipoprotein (a): Structural and Functional Consequences of Mutations in Kringle Type 10 (or Kringle 4-37)", Clinical Genetics, Vol.46, 1994, pages 42-45, totality.	1-19
A	SCANU et al. "A Single Point Mutation (Trp72=> Arg) in Human apo(a) Kringle 4-37 Associated with a Lysine Binding Defect in Lp(a)", Biochimica et Biophysica Acta, Vol 1227, 1994, pages 41-45, totality.	1-19
A	GABEL et al. "Sequences within Apolipoprotein(a) Kringle IV Types 6-8 Bind Directly to Low-Density Lipoprotein and Mediate Noncovalent Association of Apolipoprotein(a) with Apolipoprotein B-100", Biochemistry, Vol.37, 1998, pages 7892-7898, totality.	1-19
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents: „A“ document defining the general state of the art which is not considered to be of particular relevance „E“ earlier application or patent but published on or after the international filing date „L“ document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) „O“ document referring to an oral disclosure, use, exhibition or other means „P“ document published prior to the international filing date but later than the priority date claimed „T“ later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention „X“ document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone „Y“ document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art „&“ document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
5 May 2000 (05.05.2000)		2 August 2000 (02.08.2000)
Name and mailing address of the ISA/AT		Authorized officer
Austrian Patent Office		Weniger
Kohlmarkt 8-10; A-1014 Vienna		
Facsimile No. 1/53424/535		Telephone No. 1/53424/

A NOVEL ANGIOGENESIS INHIBITOR

BACKGROUND OF THE INVENTION

5

Field of the Invention

The present invention relates to a novel angiogenesis inhibitor, LK68 whose amino acid sequence is identical with the human apolipoprotein(a) kringle domains IV36, IV37 and V38, more specifically, to an amino acid sequence of the LK68, a cDNA sequence encoding the LK68, a recombinant expression vector comprising the cDNA, a recombinant microorganism transformed with the recombinant expression vector and a novel use of the LK68 as an anticancer agent and a method for treating the angiogenesis-mediated disease.

Description of the Prior Art

20

Angiogenesis is a biological process of generating new blood vessels into a tissue or organ. Under normal physiological conditions, humans or animals undergo angiogenesis only in very specific restricted situations. For example, angiogenesis is normally observed in wound healing, fetal and embryonal development and formation of the corpus luteum, endometrium and placenta. It has been reported that new vessel growth is tightly controlled by many angiogenic regulators (see: Folkman, J., Nature Med., 1: 27-31, 1995a), and the switch of the angiogenesis phenotype depends on the net balance between up-regulation of angiogenic stimulators and down-regulation of angiogenic suppressors.

An imbalance of the angiogenic process has been shown to contribute to pathological disorders such as diabetic retinopathy, rheumatoid arthritis and psoriasis (see: Folkman, J., Nature Med., 1: 27-31, 1995a).

Especially, both primary and metastatic tumors need to recruit angiogenic vessels for their growth (see: Folkman, J., New Engl. J. Med., 285:1182-1186, 1971; Folkman, J., J. Biol. Chem., 267:10931-10934, 1992). If
5 this angiogenic activity could be repressed or eliminated, then the tumor, although present, would not grow. There are many reports suggesting that inhibiting tumor angiogenesis should provide a practical approach to long term control of the disease. Blocking positive
10 regulators of angiogenesis or utilizing negative regulators to suppress angiogenesis results in a delay or regression of experimental tumors. If the angiogenic activity could be repressed or eliminated, then the tumor, although present, would not grow. Moreover, in
15 the disease state, prevention of angiogenesis could avert the damage caused by the invasion of the new microvascular system effectively. Therefore, therapies directed at control of the angiogenic process could lead to the abrogation or mitigation of these diseases.

20 Therefore, what is needed is a novel angiogenesis inhibitor which can inhibit the unwanted growth of blood vessels, especially into tumors. An anticancer agent comprising the angiogenesis inhibitor should be able to overcome the activity of endogenous growth factors in
25 premetastatic tumors and prevent the formation of the capillaries in the tumors thereby inhibiting the growth of the tumors. The anticancer agent should also be able to modulate the formation of capillaries in other angiogenic processes, such as wound healing and
30 reproduction. Finally, the anticancer agent and method for inhibiting angiogenesis should preferably be non-toxic and produce few side-effects.

Until now, at least 10 endogenous angiogenic inhibitors have been identified in the art (see:
35 O'Reilly, M. S. et al., Cell, 88: 277-285, 1997). One such molecule is angiostatin, which consists of the plasminogen kringle I through IV(see: O'Reilly, M. S.

et al., Cell, 79:315-328, 1994). When applied systemically, angiostatin powerfully inhibits both primary tumor growth and metastasis without toxicity, and angiogenesis induced by bFGF as well (see: O'Reilly, M. S. et al., Nature Med., 2:689-692, 1996). These anti-tumor effects were accompanied by a marked reduction of microvessel density within the tumor mass, indicating that suppression of angiogenesis was associated with the inhibition of tumor growth.

Kringles are protein structural domains composed of approximately 80 amino acids and three intramolecular disulfide bonds. Kringle structures are found in many proteins such as prothrombin (see: Walz, D. A. et al., Proc. Natl. Acad. Sci., U.S.A., 74:1969-1973, 1977), plasminogen (see: Ponting, C. P., Blood Coagul. & Fibrinolysis, 3:605-614, 1992), urokinase (see: Pennica, D. et al., Nature, 301:579-582 1983), hepatocyte growth factor (see: Lukker, N. A. et al., Protein Eng., 7:895-903, 1994), and apolipoprotein("apo")(a) (see: McLean, J. W. et al., Nature, 330:132-137, 1987). These domains appear to be independent folding units, but their functional role is not yet known. The previous reports represent that the kringle structure can act as inhibitors of endothelial cell migration and proliferation during angiogenesis. Specifically, prothrombin's kringle 2 and plasminogen's kringle 1-4, and 5 have been shown to be anti-angiogenic (see: Ji, W. R. et al., FASEB J., 15:1731-1738, 1998a; Ji, W. R. et al., Biochem. Biophys. Res. Commun., 247:414-419, 1998b; Cao, Y. et al., J. Biol. Chem., 271:29461-29467, 1996; Cao, Y. et al., J. Biol. Chem., 272:22924-22928, 1997; Barendsz-Janson, A. F., J. Vasc. Res., 35:109-114, 1998; Lee, T. H. et al., J. Biol. Chem., 273:28805-28812, 1998).

Apolipoprotein(a), one of the proteins having kringle structures, is a candidate for a novel angiogenesis inhibitor. Apo(a) is covalently attached to

apoB-100, the main protein component of low density lipoprotein(LDL) to form lipoprotein(a) (see: Fless, G. M., J. Biol. Chem., 261: 8712-8718, 1986). Elevated plasma concentration of Lp(a) represents a major independent risk factor for arteriosclerosis (see: Armstrong, V. W. et al., Artherosclerosis, 62:249-257, 1986; Assmann, G., Am. J. Cardiol., 77:1179-1184, 1996; Bostom, A. G. et al., JAMA, 276:544-548, 1996). Although several pathogenic activities have been reported, the physiological role of apo(a) has not yet been established (see: Lawn, R. M. et al., J. Biol. Chem., 271:31367-31371, 1996; Scanu, A. M. and Fless, G. M., J. Clin. Invest., 85:1709-1715, 1990; Utermann, G., Science, 246:0904-910, 1989).

Apo(a) contains two types of kringle domains and an inactive protease-like domains: the first 37 kringle domains are ~75% identical to plasminogen kringle IV, and the last kringle domain is 90% identical to plasminogen kringle V. Interestingly, the kringle IV-like domain is present in 15-40 copies in different human alleles of the apo(a) gene. In this regard, it is feasible to develop an inhibitor of tumor angiogenesis and growth employing the Apo(a) kringle structures.

SUMMARY OF THE INVENTION

In accordance with the present invention, the inventors have cloned and expressed the human apo(a) kringles containing IV36, IV37 and V38 as a recombinant protein LK68, and discovered that: the LK68 protein and its single kringles, LK6, LK7 and LK8, have an ability to overcome the angiogenic activity of endogenous growth factors such as bFGF *in vitro*; and they may be used as active ingredients of anticancer agents.

The first object of the invention is, therefore, to provide a novel LK68 protein consisting of human apo(a)

kringle domains IV36, IV37 and V38, and cDNA encoding the LK68 protein.

The second object of the invention is to provide a novel recombinant vector containing the cDNA encoding human apo(a) kringle domains IV36, IV37 and V38.

The third object of the invention is to provide an anticancer agent which comprises the LK68 protein or its single kringles, LK6, LK7 and LK8, as an active ingredient.

The fourth object of the invention is to provide a method for treating angiogenesis-mediated disease by employing the LK68 protein.

BRIEF DESCRIPTION OF THE DRAWINGS

The above and the other objects and features of the present invention will become apparent from the following description given in conjunction with the accompanying drawings, in which:

Figure 1 is a photograph of a SDS-polyacrylamide gel electrophoresis for analysis of recombinant LK68 protein expressed in *E. coli*.

Figure 2 is a photograph showing the inhibition of angiogenesis by LK68 on the chick chorioallantoic membrane (CAM).

Figure 3(A) is a graph showing inhibition of vessel growth in the CAM as a function of LK68.

Figure 3(B) is a graph showing inhibition of vessel growth in the CAM as a function of single kringles, LK6, LK7, LK8, and a control.

Figure 4(A) is a graph showing inhibition of BCE cell proliferation by recombinant LK68 and angiostatin.

5

Figure 4(B) is a graph showing inhibition of BCE cell proliferation by recombinant LK6, LK7 and LK8.

10

Figure 4(C) is a graph showing inhibition of HUVEC cell proliferation by recombinant LK68 and LK8.

15

Figure 5(A) is a graph showing BrdU labeling index of LLC cells in the presence of recombinant LK68 and LK8.

20

Figure 5(B) is a graph showing BrdU labelling index of Y1 cells in the presence of recombinant LK68 and LK8.

25

Figure 5(C) is a graph showing BrdU labelling index of TIB74 cells in the presence of recombinant LK68 and LK8.

30

Figure 5(D) is a graph showing BrdU labelling index of CHO cells in the presence of recombinant LK68 and LK8.

35

Figure 5(E) is a graph showing BrdU labelling index of MSF cells in the presence of recombinant LK68 and LK8.

Figure 5(F) is a graph showing BrdU labelling index of NIH3T3 cells in the presence of recombinant LK68 and LK8.

Figure 6(A) is a graph showing inhibition of HUVEC cell migration by recombinant LK68, LK8 and PK5.

5 Figure 6(B) is a graph showing inhibition of HUVEC cell migration by recombinant LK68, LK6, LK7 and LK8.

10 Figure 7 is a graph showing inhibition of BCE cell migration by angiostatin, recombinant LK68, LK6, LK7, and LK8 and combination of single kringles.

15 Figure 8 shows the effect of administration of LK68 to mice having implanted Lewis lung carcinoma cells on total volume as a function of time.

20 Figures 9(A) to 9(C) are photographs showing histological analyses of Lewis lung carcinoma cells by hematoxylin and eosin (H/E) staining.

25 Figure 10 shows the effect of administration of LK68 to nude mice having implanted human lung carcinoma A549 cells on total volume as a
30 function of time.

DETAILED DESCRIPTION OF THE INVENTION

35 The present invention provides a novel protein LK68, which can be cloned and expressed as recombinant protein from the human apolipoprotein("apo")(a) kringles. The LK68 protein consists of amino acid sequences of human

apolipoprotein(a) kringle domains IV36(amino acid 8 to 80), IV37(amino acid 122 to 194) and V38(amino acid 226 to 300) in a serial manner(see: SEQ ID NO: 2). The first two kringle domains of LK68 (i.e., IV36 and IV37) are
5 homologous to human plasminogen kringle IV, and the third kringle domain V38 is homologous to human plasminogen kringle V. The present invention also provides a cDNA encoding the LK68 protein (see: SEQ ID NO: 1) and recombinant vectors which comprises the said
10 cDNA and expression vectors such as pET vector series.

In describing the kringle domains of the invention, human apolipoprotein(a) kringles IV36, IV37 and V38 are abbreviated as KIV36, KIV37 and KV38, respectively; LK68 is employed to mean the recombinant protein which
15 comprises the said three kringle domains; and, LK6, LK7 and LK8 are employed to mean the recombinant proteins of KIV36, KIV37 and KV38, respectively.

Because apolipoprotein(a) contains plasminogen-type IV and V kringle domains, it was assumed that
20 apolipoprotein(a) could possibly have an anti-angiogenic activity. There is an experimental evidence suggesting apolipoprotein(a) may contain biological activity as an inhibitor of tumor angiogenesis and growth(see: Trieu, V. N. and Uckun, F. M., Biochem. Biophys. Res. Commun.,
25 257:714, 1999). It has been reported that LL/2(Lewis Lung Carcinoma) tumor growth is delayed in apo(a) transgenic mice and the microvessel density of LL/2 tumors from apo(a) transgenic mice is lower than that from wild-type mice as control.

30 Under the circumstance, the present inventors assumed that LK68 protein, its single kringles or their functional equivalents may have an anti-angiogenic activity. To verify said anti-angiogenic activity, it was investigated whether recombinant LK68 and its single
35 kringles (i.e., LK6, LK7 and LK8) are potent anti-angiogenic factors *in vitro* and *in vivo* as well. As a result, LK68, LK6, LK7 and LK8 exhibit inhibitory

activities on the cultured endothelial cell proliferation as well as on the endothelial cell migration. LK68 and its single kringles also inhibit the normal development of capillaries in the chick embryo chorioallantoic membrane (CAM). It was also shown that systemic administration of LK68 inhibited the primary tumor growth, which is correlated with a suppression of tumor-induced angiogenesis. Since each of the single kringle proteins, LK6, LK7 and LK8 showed anti-angiogenic activity, it is expected that they also inhibit the primary tumor growth or metastasis.

Accordingly, LK68 protein, its single kringles or their functional equivalents may be applied for the development of a potent anti-cancer agent, which is highly effective for angiogenesis-mediated diseases covering rheumatoid arthritis, psoriasis, or ocular angiogenic diseases, etc.

Also, LK68 protein, its single kringles or their functional equivalents may be used in combination with other compositions and procedures for the treatment of diseases. For example, tumor may be treated conventionally with surgery, radiation or chemotherapy combined with LK68, its single kringles, or their functional equivalent, and then LK68, its single kringles, or their functional equivalent may be subsequently administered to the patient to extend the dormancy of micrometastases and to stabilize and inhibit the growth of any residual primary tumor.

The present invention is further illustrated in the following examples, which should not be taken to limit the scope of the invention.

Example 1: Cloning and Expression of Recombinant LK68

35

In order to verify the anti-angiogenic activity of human apo(a) kringle, the inventors cloned and expressed

the last three kringles containing IV36, IV37 and V38 as a recombinant protein LK68. A DNA fragment of apo(a) spanning nucleotides 12,052 to 12,975 (see: McLean J. W. et al., Nature, 330:132, 1987) was PCR-amplified from human liver cDNA and the resulting 924-bp *NdeI*-*BamHI* fragment was ligated into *E.coli* expression vector pET11a(Novagen, USA). The oligonucleotide primers A(SEQ ID NO: 9) and F(SEQ ID NO: 14) (see: Table 1) were used for PCR amplification under the standard PCR protocol. This clone was named "pET11a/LK68", which encodes 308 amino acids including human apo(a) kringle domains, IV36, IV37 and V38 (see: SEQ NO ID: 2). The first two kringle domains of this clone, IV36 and IV37, are homologous to human plasminogen kringle IV, and the third kringle domain V38 is homologous to human plasminogen kringle V.

The nucleotide sequences of this clone were confirmed in both directions. When the nucleotide sequence of this clone was compared to the same region of the human apo(a) (see: McLean J. W. et al., Nature, 330:132, 1987), the nucleotide sequences are identical with the exception of a single base change at nucleotide 554. Our clone contains a cytosine at this position as compared to a thymidine in the sequence reported by McLean et al. (see: McLean J. W. et al., Nature, 330:132, 1987), causing an amino acid change to Thr from Met. This substitution has also been reported by other groups (see: Van der-Hoek, Y. Y. et al., Hum. Mol. Genet., 2:361-366, 1993; LoGrasso, P. V. et al., J. Biol. Chem., 269:21820-21827, 1994) and appears to be the predominant allele for apo(a).

E. coli BL21(DE3) was transformed with an expression plasmid pET11a/LK68 and recombinant LK68 protein was expressed under the following conditions. One liter of Luria-Bertani broth containing ampicillin was inoculated with 10ml of an overnight culture of *E. coli* BL21(DE3) harboring the pET11a/LK68 plasmid and incubated with shaking at 37°C. When the OD₆₀₀ of the

culture reached 0.4-0.6, isopropylthio- β -D-galactoside(IPTG) was added at a final concentration of 1mM. Cells were grown an additional 4h after induction. Cells were harvested by centrifugation at 8000xg for 5 30min at 4°C. These cell pellets were sonicated and the over-expressed proteins were analyzed by SDS-PAGE(see: Figure 1). In Figure 1, Mr represents a molecular weight marker(Boehringer Mannheim, Germany); lane 1, the expression of recombinant LK68 protein without IPTG 10 induction; and, lane 2, the expression of recombinant LK68 protein with IPTG induction, respectively. Recombinant LK68 protein having a molecular weight of 37kDa was well expressed in *E. coli*, accumulating to about 20-30% of the total protein, as evidenced by image 15 analysis of the scanned gel. The transformant thus prepared was designated as '*Escherichia coli* BL21/LK6-8', and deposited with the Korean Collection for Type Cultures, #52 Oun-dong, Yusong-ku, Taejon 305-333, Republic of Korea, an international depository authority 20 as accession No. KCTC0633BP on Jun. 9, 1999.

Each of single kringle domains, IV36, IV37 and V38, was cloned separately into an expression vector pET15b as described above. The oligonucleotide primers used for 25 cloning are listed in Table 1: that is, A(SEQ ID NO: 9) and D(SEQ ID NO: 12) for KIV36 cloning; B(SEQ ID NO: 10) and E(SEQ ID NO: 13) for KIV37 cloning; and, C(SEQ ID NO: 11) and F(SEQ ID NO: 14) for KV38 cloning, respectively. These three couples of oiligonucleotide 30 primers were used for PCR amplification under the standard PCR protocol and the resulting clones were named "pET15b/LK6", "pET15b/LK7" and "pET15b/LK8", each of which includes the single human apo(a) kringle domains of IV36, IV37 and V38, respectively. *E. coli* 35 BL21(DE3) competent cells were transformed with each of the expression plasmid, pET15b/LK6, pET15b/LK7 and pET15b/LK8. The transformant with plasmid pET15b/LK6

thus prepared was designated as '*Escherichia coli* BL21(DE3)/LK6', and deposited with the Korean Collection for Type Cultures, #52 Oun-dong, Yusong-ku, Taejon 305-333, Republic of Korea, an international depository authority as accession No. KCTC0655BP on Sept. 3, 1999. The transformant with plasmid pET15b/LK7 thus prepared was designated as '*Escherichia coli* BL21(DE3)/LK7', and deposited with the Korean Collection for Type Cultures on the same address as above, an international depository authority as accession No. KCTC0656BP on Sept. 3, 1999. The transformant with plasmid pET15b/LK8 thus prepared was designated as '*Escherichia coli* BL21/LK8', and deposited with the Korean Collection for Type Cultures on the same address as above, an international depository authority as accession No. KCTC0634BP on Jun. 9, 1999.

Recombinant LK6, LK7 and LK8 proteins were expressed under the same conditions as fusion proteins containing N-terminal His-tag. Each of the over-expressed recombinant LK6, LK7 and LK8 protein was purified using pET His-tag system under the manufacturer's recommended condition.

Table 1. Oligonucleotide primers used for PCR cloning

Nucleotide Sequences*	Description	Location**	SEQ
			ID NO.
A. TCCATATGAAAAGCCCTGTGGTCCAGGAT	K36-5'	12052-12072	9
B. CAGTCCATATGGTCCGCCAGTGCTACCATGGCA	K37-5'	12406-12427	10
C. GGAATTCATATGGAACAGGACTGCATGTTT	K38-5'	12718-12735	11
D. CGGGATCCTTAACCTGATTCTGTTTC	K36-3'	12310-12323	12
E. CGGGATCCTTAGACCACAGTCCCTTC	K37-3'	12658-12671	13
F. CGGGATCCTTAAGAGGATGCACA	K38-3'	12964-12975	14

* Restriction sites, NdeI and BamHI are added for the cloning

conveniences(underlined).

** See: McLean et al., Nature, 330:132, 1987, for nucleotide sequence(accession number is X06290).

5 Example 2: Purification of the Recombinant LK68

In order to produce the recombinant LK68, high cell-density fermentation was performed in a 5L Bioflow III bioreactor(New Brunswick Scientifics, Edison, USA) in the following medium: 4%(w/v) yeast extract, 4%(w/v) glycerol, 1%(w/v) dibasic sodium phosphate, 0.2%(w/v) monobasic potassium phosphate and 50 μ g/ml ampicillin. When the cells reached an absorbance of 100 at 600 nm, protein expression was induced with 1mM IPTG and then DO-stat fed-batch was carried out for 9h with feed media(29%(w/v) yeast extract, 39%(w/v) glycerol and 0.5%(w/v) magnesium sulfate. Cells were harvested by centrifugation at 8000xg for 30 min. Each fermentation process yielded about 80g of cell/L(wet weight).

To assess if LK68 was expressed in the soluble fraction or the insoluble cellular fraction of *E.coli* cells, the inventors analyzed the LK68 expression in these fractions. This analysis showed that LK68 was located in the insoluble cellular fraction. Thus, it was necessary to denature, refold and reoxidize the disulfied bonds of LK68. By using the deoxycholate and other detergents, the insoluble LK68 protein was purified as inclusion bodies to the extent of >95% purity. Then, the inclusion bodies were solublized with 7M urea and folded into native conformation using a rapid dilution and an equilibrium dialysis scheme. In the folding buffer, purified inclusion bodies were easily refolded without detectable protein aggregation. After the dialysis, the protein was purified by lysine-Sepharose 4B affinity chromatography. The protein bound to lysine-Sepharose was specifically eluted by ϵ -ACA(ϵ -amino-n-caproic acid). This suggested that the lysine-

binding site located in the KIV37 kringle of the refolded protein was fully functional. Affinity elution of LK68 with 0.1M ϵ -ACA yielded about 3mg of protein/g of cells(wet weight). Chromatography with polymyxin-B
5 beads(Sigma Chemical Co., USA) was subsequently performed to eliminate any endotoxin, and residual endotoxin activity was determined with the *Limulus* amebocyte lysate assay kit(Biowhittaker Inc., USA). The purified protein was analyzed by SDS-PAGE and was stored
10 at -20°C until needed. The calculated pI value of LK68 protein is 6.13. The N-terminal amino acid sequence of the purified LK68 was confirmed by amino acid sequencing.

Example 3: Chick Chorioallantoic Membrane Assay

15

In order to determine whether LK68 is anti-angiogenic *in vivo*, the inventors tested its ability to inhibit the development of capillaries in the chorioallantoic membrane("CAM")(see: Lee, T. H. et al.,
20 J. Biol. Chem., 273:28805-28812, 1998). Fertilized three-day-old eggs were incubated at 37°C, and a window was made after the extraction of ovalbumin. After two days of incubation, a Thermanox coverslip(Nunc Inc., USA) containing recombinant LK68 protein was applied to
25 the CAM of individual embryos. After 48h, 20% fat emulsion was injected into the chorioallantois of the embryos, and the vessel formation around the Thermanox was examined(see: Figure 2). In Figure 2, the left photograph shows the normal development of capillaries
30 in the CAM; and, the right shows the inhibition of angiogenesis by LK68 on CAM, respectively.

When LK68 at the dose range of 3 - 5 μ g was applied on the CAM, more than 60 % among the 100 eggs tested showed avascular zone around the sample applied,
35 indicating that the growth of capillaries was inhibited. With the recombinant proteins of each kringle domain, e.g. LK6, LK7 or LK8, 60 - 70% of the eggs tested showed

inhibitory effects at the dose range of 1µg/CAM(see: Figures 3(A) and 3(B)). This in vivo study showed that apo(a) kringle domains have anti-angiogenic activity and LK68 as well as single kringle proteins is a potent
5 inhibitor of angiogenesis. There was no evidence of toxicity in any of the chick embryos tested.

Example 4: Inhibition of Endothelial Cell Proliferation

10 Recombinant LK68, LK6, LK7 and LK8 proteins were assayed for their inhibitory activity on proliferation of bovine capillary endothelial (BCE) cells stimulated by bFGF under the following conditions. BCE cells were grown in DMEM containing 10% bovine calf serum (BCS) and
15 3 ng/ml bFGF(Upstate Biotechnology, USA). Approximately 3,000 cells were added to each well of 96-well tissue culture plate and incubated at 37 °C in 5% CO₂ atmosphere. After incubation for 18 h, the medium was replaced with DMEM containing 0.5% BCS, and the test samples were
20 added to each well. After 30 min incubation, bFGF was added to a final concentration of 1ng/ml. The cell count was determined by [³H]thymidine incorporation method. The experiments were performed in triplicate.

As can be seen in Figure 4, it was determined that
25 LK68, LK6, LK7 and LK8 specifically inhibited BCE cell proliferation in a dose-dependent manner. When the angiostatin was applied as a positive control, all the Apo(a) kringle proteins tested appeared to be more effective under the conditions used in this experiment.
30 The concentration of half-maximal inhibition (ED₅₀) for LK68 is determined about 200 - 250nM, about 140 - 170nM for LK6, about 10 - 20nM for LK7, and about 10 - 20nM for LK8 (see: Figures 4(A) and 4(B)).

Recombinant LK68 and LK8 proteins were assayed for
35 their inhibitory activity on proliferation of human umbilical vein endothelial (HUVEC) cells stimulated by bFGF under the following conditions. HUVECs(American

Type Culture Collection, USA) were grown in F12K medium containing 10% heat-inactivated fetal bovine serum("FBS")(Hyclone, USA), 30 μ g/ml endothelial cell growth supplement(ECGS)(Sigma Chemical Co., USA), and 100 μ g/ml heparin(Sigma Chemical Co., USA). The cells were plated at a density of 2000/well in 96-well tissue culture plate. The cells were incubated at 37°C, 5% CO₂, for 18hr, washed once with serum-free medium, and F12 medium containing 0.5% FBS was added. The cells were treated with various concentrations of samples and incubated for 30min. Then, ECGS, heparin and bFGF(Upstate Biotechnology, USA) were added into the cells with the final concentrations of 30 μ g/ml, 100 μ g/ml and 5ng/ml, respectively. After 48hr of incubation, cell counts were determined with the Cell Proliferation ELISA using 5-bromo-2'- deoxyuridine (BrdU)(Boehringer Mannheim, USA). The experiments were performed in triplicate.

As can be seen in Figure 4(C), it was determined that LK68 as well as LK8 specifically inhibited HUVEC cell proliferation in a dose-dependent manner.

In the presence of LK68 or single kringle proteins such as LK6, LK7 and LK8, the morphology of BCE or HUVEC cells appeared similar to those of untreated cells. In addition, cell proliferation can be rescued with bFGF stimulation after removal of LK68. These results indicate that LK68 as well as single kringle proteins are not cytotoxic to capillary endothelial cells. Furthermore, the inhibitory activity would appear to be specific for endothelial cells, e.g., BCE and HUVEC cells. Additionally, LK68 as well as LK8 failed to show inhibition of proliferation of non-endothelial cell types, such as CHO cells, mouse skin fibroblast NIH3T3 cells, mouse Lewis lung carcinoma cells, mouse adrenal tumor Y1 cells and mouse embryonic liver/SV40 transformed cell line TIB74(see: Figures 5(A) to 5(F)). Figures 5(A) to 5(C) represent the sensitivity of

various tumor cells such as LLC, Y1, and TIB 74, and Figures 5(D) to 5(F) represent the sensitivity of various normal cell lines such as CHO, MSF, and NIH3T3, respectively.

5

Example 5: Inhibition of Endothelial Cell Migration

Cell migration assay was performed in Transwells with 8-mm pores (Costar, USA). Briefly, the wells were
10 coated with fibronectin(25 μ g/ml)(Sigma Chemical Co., USA) overnight and HUVECs were plated at a density of 2000/well in 100 μ l Dulbecco's modified Eagle's medium containing 0.4% fetal calf serum(FCS) in the upper chamber. 500 μ l of DMEM containing 0.4% FCS was added to
15 the lower chamber and incubated at 37°C for 1 hr. The test samples of 1 μ M concentration were added to the upper chamber and 25 ng/ml of bFGF was added to the lower chamber. After 5 hr incubation, cells that crossed the fibronectin-plated membrane were quantified after
20 wiping off the cells in the upper chamber with a cotton swab. The cells across the membrane were stained with Diff-Quik stain set according to the manufacturer's instruction (Dade Behring Inc., USA) and were counted at 100x magnification. The experiments were performed in
25 duplicate.

Basic FGF(25ng/ml) was used to stimulate the migration of HUVEC cells. With the dose of 1 μ M, LK68 as well as single kringle proteins such as LK6, LK7 and LK8 completely inhibited the bFGF-induced HUVEC cell
30 migration to the level of uninduced control(see: Figures 6(A) and 6(B)). In Figure 6, (-)CON represent uninduced control, and (+)CON represent bFGF-induced positive control.

Migration assay using BCE cells was performed as
35 described above. Two different concentrations of LK68 or single kringle proteins applied and all the Apo(a) kringle proteins tested showed inhibitory effects on BCE

cell migration. In addition, LK68 and its single kringle proteins were more effective on the inhibition of BCE cell migration than angiostatin(AS) (see: Figure 7).

5 Example 6: Suppression of Primary Tumor Growth

Example 6-1: Lewis Lung Carcinoma

Male 6 to 8-week-old C57BL6/J mice were implanted
10 with Lewis lung carcinomas. The subcutaneous dorsa of mice in the proximal midline were injected with 1×10^6 cells in 0.1ml of saline. When the tumors reached about 5mm in diameter, tumor-bearing mice received LK68 (100 mg/kg body weight) as a suspension in PBS injected
15 subcutaneously at a site distant from the tumor. The control group of mice had only a sham procedure and was treated with PBS only. Tumor size was measured every day during the treatment; and, volumes were determined using the formula $\text{width}^2 \times \text{length} \times 0.52$ and the ratio of
20 treated to control tumor volume(T/C) was determined for the last time point. Treatments were continued for 8 days, at which point all mice were sacrificed and the tumors were removed(see: Figure 8). As can be seen in Figure 8, it was clearly determined that the growth of
25 LLC primary tumors was potently suppressed by systemic LK68 therapy; LK68 at a dose of 100mg/kg caused significant regression of tumor burden only with 7 day treatment.

Histological analyses were also carried out to
30 compare tumors from treated and control mice in terms of vessel density and hemorrhage formation, and morphological appearance(see: Figures 9(A) to 9(C)). In Figures 9(A) to 9(C), 9(A) shows PBS-treated control, 9(B) LLC tumors of 10mg/kg body weight LK68-treated, and
35 9(C) LLC tumor of 100mg/kg body weight LK68-treated, respectively. Obvious histological differences were observed in LK68-treated tumors by hemotoxylin and

eosin(H/E) staining: that is tumor cells were not intact and morphologically not viable; and, zonal necrosis was examined around the tumors. Also, vessel density within LK68-treated tumors was reduced. There was no evidence
5 of inflammation or bleeding in any of the mice treated with the recombinant LK68.

Example 6-2: Human Lung Carcinoma

10 Four-week-old outbred female *nu/nu* nude mice used in this experiment were housed in a sterile environment. Cages, bedding, food and water were all autoclaved. The mice were maintained on a 12-hr light/ 12-hr dark cycle. Human lung cancer cells (A549 purchased from Korean Cell
15 Line Bank) were maintained in RPMI 1640 medium, supplemented with 10% heat-inactivated FBS and antibiotics. Approximately 2×10^7 cells of A549 human lung carcinoma were subcutaneously injected into nude mice into the proximal midline of the dorsa. When tumors
20 were palpable at day 7 after tumor implantation, the mice were treated with LK68 at the dose of 100mg/kg body weight. The control group was treated with PBS only. The treatment was continued for 17 days. The tumor size was measured every other day.

25 The tumor growth was regressed by the LK68 treatment: that is, LK68-treated A549 tumors were approximately 57.5% smaller than tumors in control animals(see: Figure 10). There was no evidence of any toxicity in any of the treated mice. Continued therapy
30 maintained the tumors in a state of dormancy for as long as it was administered. These data strongly suggest that the anti-angiogenic effect of LK68 can be used to target a wide variety of primary malignancies.

35 As clearly illustrated and demonstrated as above, the present invention provides a novel angiogenesis inhibitor, LK68 whose amino acid sequence is identical

with the human apo(a) kringle domains IV36, IV37 and V38,
a DNA sequence encoding the LK68, a recombinant
expression vector comprising the DNA, a recombinant
microorganism transformed with the recombinant
5 expression vector, use of the LK68 as an anticancer
agent, and a method for treating angiogenesis-mediated
disease.


BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT
OF MICROORGANISMS FOR THE PURPOSE OF PATENT PROCEDURE

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT

issued pursuant to Rule 7.1

TO: Mogen Biotechnology Research Institute
#241, Pojung-ri, Kookung-myun, Yongin-si, Kyonggi-do 449-910,
Republic of Korea

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: <i>Escherichia coli</i> BL21(DX3)/LEB	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: KCTC 0355BP
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I above was accompanied by: [x] a scientific description [] a proposed taxonomic designation (Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on Sep 03 1999 .	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depositary Authority on and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: Korean Collection for Type Cultures Address: Korea Research Institute of Bioscience and Biotechnology (KRIBB) #52, Oun-dong, Yusong-ku, Taejeon 305-333, Republic of Korea	Signature(s) of person(s) having the power to represent the International Depositary Authority of authorized official(s):  BAE, Kyung Sook, Director Date: Sep 08 1999


BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT
OF MICROORGANISMS FOR THE PURPOSE OF PATENT PROCEDURE

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT

issued pursuant to Rule 7.1

TO: Mogam Biotechnology Research Institute
#341, Pojung-ri, Kosung-myun, Yongin-si, Kyonggi-do 449-910,
Republic of Korea

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: <i>Escherichia coli</i> BL21(DE3)/LK7	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: KCTC 0856BP
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I above was accompanied by: [x] a scientific description [] a proposed taxonomic designation (Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on Sep 08 1999 .	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depositary Authority on and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: Korean Collection for Type Cultures Address: Korea Research Institute of Bioscience and Biotechnology (KRIBB) #52, Oun-dong, Yusong-ku, Taejeon 305-333, Republic of Korea	Signature(s) of person(s) having the power to represent the International Depositary Authority of authorized official(s):  BAE, Kyung Sook, Director Date: Sep 08 1999


BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT
OF MICROORGANISMS FOR THE PURPOSE OF PATENT PROCEDURE

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT

issued pursuant to Rule 7.1

TO: Mogam Biotech. Research Institute
#341, Pongung-ri, Koosung-myun, Yongin-si, Kyonggi-do 449-910,
Republic of Korea

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: <i>Escherichia coli</i> BL21/LK8	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: KCTC 0634BP
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I above was accompanied by: [x] a scientific description [] a proposed taxonomic designation (Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on Jun 09 1999 .	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depositary Authority on and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: Korean Collection for Type Cultures Address: Korea Research Institute of Bioscience and Biotechnology (KRIBB) #52, Oun-dong, Yusong-ku, Taejon 305-333, Republic of Korea	Signature(s) of person(s) having the power to represent the International Depositary Authority of authorized official(s):  BAE, Kyung Sook, Director Date: Jun 16 1999


BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT
OF MICROORGANISMS FOR THE PURPOSE OF PATENT PROCEDURE

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT

issued pursuant to Rule 7.1

TO: Mogan Biotech. Research Institute
#341, Pojung-ri, Kongsung-myun, Yongin-si, Kyonggi-do 449-910,
Republic of Korea

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: <i>Escherichia coli</i> BL21/LK6-8	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: KCTC 0633BP
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I above was accompanied by: [x] a scientific description [] a proposed taxonomic designation (Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on Jun 09 1999 .	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depositary Authority on and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: Korean Collection for Type Cultures Address: Korea Research Institute of Bioscience and Biotechnology (KRIBB) #52, Oun-dong, Yusong-ku, Taejon 305-333, Republic of Korea	Signature(s) of person(s) having the power to represent the International Depositary Authority of authorized official(s):  BAE, Kyung Sook, Director Date: Jun 16 1999

WHAT IS CLAIMED IS:

1. LK6 protein (SEQ ID NO: 4) consisting of amino
acid sequences of human apolipoprotein(a) kringle
5 domains IV36.

2. LK7 protein (SEQ ID NO: 6) consisting of amino
acid sequences of human apolipoprotein(a) kringle
domains IV37.
10

3. LK8 protein (SEQ ID NO: 8) consisting of amino
acid sequences of human apolipoprotein(a) kringle
domains V38.

4. LK68 protein (SEQ ID NO: 2) consisting of amino
acid sequences of human apolipoprotein(a) kringle
domains IV36, IV37 and V38 in a serial manner
15

5. A cDNA sequence (SEQ ID NO: 3) which codes for
the LK6 protein of claim 1.
20

6. A cDNA sequence (SEQ ID NO: 5) which codes for
the LK7 protein of claim 2.

7. A cDNA sequence (SEQ ID NO: 7) which codes for
the LK8 protein of claim 3.
25

8. A cDNA sequence (SEQ ID NO: 1) which codes for
the LK68 protein of claim 4.
30

9. A recombinant expression vector pET15b/LK6
comprising the cDNA of claim 5 which expresses the LK6
protein of claim 1.

10. A recombinant expression vector pET15b/LK7
comprising the cDNA of claim 6 which expresses the LK7
protein of claim 2.
35

11. A recombinant expression vector pET15b/LK8 comprising the cDNA of claim 7 which expresses the LK8 protein of claim 3.

5

12. A recombinant expression vector pET11a/LK68 comprising the cDNA of claim 8 which expresses the LK68 protein of claim 4.

10 13. *Escherichia coli* BL21(DE3)/LK6(KCTC0655BP) transformed with the recombinant expression vector pET15b/LK6 of claim 9.

14. *Escherichia coli* BL21(DE3)/LK7(KCTC0656BP)
15 transformed with the recombinant expression vector pET15b/LK7 of claim 10.

15. *Escherichia coli* BL21/LK8(KCTC0634BP)
transformed with the recombinant expression vector
20 pET15b/LK8 of claim 11.

16. *Escherichia coli* BL21/LK6-8(KCTC0633BP)
transformed with the recombinant expression vector
pET11a/LK68 of claim 12.

25

17. An anticancer agent which comprises an active ingredient of LK68 protein, its single kringles, or their functional equivalents and pharmaceutically acceptable carrier.

30

18. A method for treating angiogenesis-mediated disease which comprises administering therapeutically effective amount of LK 68 protein, its single kringles, or their functional equivalents to a human or animal.

35

19. The method for treating angiogenesis-mediated disease of claim 18, wherein the angiogenesis-mediated

disease is cancer, rheumatoid arthritis, psoriasis, or ocular angiogenic disease.

1/12




FIG. 1

2/12




FIG. 2

3/12




FIG. 3 (A)




FIG. 3 (B)

4/12




FIG. 4 (A)




FIG. 4 (B)

5/12




FIG. 4 (C)

6/12




FIG. 5 (A)




FIG. 5 (B)




FIG. 5 (C)

7/12




FIG. 5 (D)




FIG. 5 (E)




FIG. 5 (F)

8/12




FIG. 6 (A)




FIG. 6 (B)

9/12




FIG. 7

10/12

Suppression of LLC by LK68




FIG. 8

11/12




FIG. 9(A)




FIG. 9(B)




FIG. 9(C)

12/12

Tumor suppression by LK 6-8 (hlung carcinoma)




FIG. 10

SEQUENCE LISTING

<110> Mogam Biotechnology Research Institute et al
5
<120> A NOVEL ANGIOGENESIS INHIBITOR

<160> 14

10 <170> KOPATIN 1.5

<210> 1
<211> 924
<212> DNA
15 <213> Homo sapiens

<400> 1
aaaagccctg tggccagga ttgctaccat ggtgatggac ggagttatcg aggcataatcc 60
20 tccaccactg tcacaggaag gacctgtcaa tcttgggtcat ctatgatacc aactggcat 120
cagaggaccc cagaaaacta cccaaatgct ggctgaccg agaactactg caggaatcca 180
gattctggga aacaaccctg gtgttacaca accgatccgt gtgtgagggtg ggagtactgc 240
25 aatctgacac aatgctcaga aacagaatca ggtgtcctag agactccac tgttgttcca 300
gttccaagca tggagggtca ttctgaagca gcaccaactg agcaaacccc tgtggtccgc 360
30 cagtgtacc atggcaatgg ccagagttat cgaggcacat tctccaccac tgtcacagga 420
aggacatgtc aatcttggtc atccatgaca ccacaccggc atcagaggac cccagaaaac 480
tacccaaatg atggcctgac aatgaactac tgcaggaatc cagatgccga tacaggccct 540
35 tgggtgttta ccacggaccc cagcatcagg tgggagtact gcaacctgac gcgatgtca 600

gacacagaag ggactgtggt cgctcctccg actgtcatcc aggttccaag cctagggcct 660
 ccttctgaac aagactgtat gtttggaat gggaaaggat accggggcaa gaaggcaacc 720
 5 actgttactg ggacgccatg ccaggaatgg gctgcccagg agcccatag acacagcacg 780
 ttcatccag ggacaaataa atgggcaggt ctggaaaaaa attactgccg taaccctgat 840
 ggtgacatca atggtcctg gtgctacaca atgaatccaa gaaaactttt tgactactgt 900
 10 gatatccctc tctgtgcatc ctct 924

<210> 2
 15 <211> 308
 <212> PRT
 <213> Homo sapiens

<400> 2
 20 Lys Ser Pro Val Val Gln Asp Cys Tyr His Gly Asp Gly Arg Ser Tyr
 1 5 10 15

Arg Gly Ile Ser Ser Thr Thr Val Thr Gly Arg Thr Cys Gln Ser Trp
 20 25 30

25 Ser Ser Met Ile Pro His Trp His Gln Arg Thr Pro Glu Asn Tyr Pro
 35 40 45

Asn Ala Gly Leu Thr Glu Asn Tyr Cys Arg Asn Pro Asp Ser Gly Lys
 30 50 55 60

Gln Pro Trp Cys Tyr Thr Thr Asp Pro Cys Val Arg Trp Glu Tyr Cys
 65 70 75 80

35 Asn Leu Thr Gln Cys Ser Glu Thr Glu Ser Gly Val Leu Glu Thr Pro
 85 90 95

Thr Val Val Pro Val Pro Ser Met Glu Ala His Ser Glu Ala Ala Pro
100 105 110

5 Thr Glu Gln Thr Pro Val Val Arg Gln Cys Tyr His Gly Asn Gly Gln
115 120 125

Ser Tyr Arg Gly Thr Phe Ser Thr Thr Val Thr Gly Arg Thr Cys Gln
130 135 140

10 Ser Trp Ser Ser Met Thr Pro His Arg His Gln Arg Thr Pro Glu Asn
145 150 155 160

Tyr Pro Asn Asp Gly Leu Thr Met Asn Tyr Cys Arg Asn Pro Asp Ala
165 170 175

15 Asp Thr Gly Pro Trp Cys Phe Thr Thr Asp Pro Ser Ile Arg Trp Glu
180 185 190

Tyr Cys Asn Leu Thr Arg Cys Ser Asp Thr Glu Gly Thr Val Val Ala
20 195 200 205

Pro Pro Thr Val Ile Gln Val Pro Ser Leu Gly Pro Pro Ser Glu Gln
210 215 220

25 Asp Cys Met Phe Gly Asn Gly Lys Gly Tyr Arg Gly Lys Lys Ala Thr
225 230 235 240

Thr Val Thr Gly Thr Pro Cys Gln Glu Trp Ala Ala Gln Glu Pro His
245 250 255

30 Arg His Ser Thr Phe Ile Pro Gly Thr Asn Lys Trp Ala Gly Leu Glu
260 265 270

Lys Asn Tyr Cys Arg Asn Pro Asp Gly Asp Ile Asn Gly Pro Trp Cys
35 275 280 285

Tyr Thr Met Asn Pro Arg Lys Leu Phe Asp Tyr Cys Asp Ile Pro Leu

290

295

300

Cys Ala Ser Ser

305

5

<210> 3

<211> 273

<212> DNA

10 <213> Homo sapiens

<400> 3

aaaagccctg tgggtccagga ttgctacat ggtgatggac ggagttatcg aggcatatcc 60

15 tccaccactg tcacaggaag gacctgtcaa tcttggatcat ctatgatacc aactggcat 120

cagaggaccc cagaaaacta cccaaatgct ggcctgaccg agaactactg caggaatcca 180

gattctggga aacaaccctg gtgttacaca accgatccgt gtgtgaggtg ggagtactgc 240

20

aatctgacac aatgctcaga aacagaatca ggt 273

<210> 4

25 <211> 91

<212> PRT

<213> Homo sapiens

<400> 4

30 Lys Ser Pro Val Val Gln Asp Cys Tyr His Gly Asp Gly Arg Ser Tyr

1

5

10

15

Arg Gly Ile Ser Ser Thr Thr Val Thr Gly Arg Thr Cys Gln Ser Trp

20

25

30

35

Ser Ser Met Ile Pro His Trp His Gln Arg Thr Pro Glu Asn Tyr Pro

35

40

45

Asn Ala Gly Leu Thr Glu Asn Tyr Cys Arg Asn Pro Asp Ser Gly Lys
 50 55 60

5 Gln Pro Trp Cys Tyr Thr Thr Asp Pro Cys Val Arg Trp Glu Tyr Cys
 65 70 75 80

Asn Leu Thr Gln Cys Ser Glu Thr Glu Ser Gly
 85 90

10

<210> 5

<211> 267

<212> DNA

15 <213> Homo sapiens

<400> 5

gtccgccagt gctacatgg caatggccag agttatcgag gcacattctc caccactgtc 60

20 acaggaagga catgtcaatc ttggatcatcc atgacaccac accggcatca gaggacccca 120

gaaaactacc caaatgatgg cctgacaatg aactactgca ggaatccaga tgccgataca 180

ggcccttgggt gttttaccac ggaccccagc atcaggtggg agtactgcaa cctgacgcga 240

25

tgctcagaca cagaaggac tgtggtc 267

<210> 6

30 <211> 89

<212> PRT

<213> Homo sapiens

<400> 6

35 Val Arg Gln Cys Tyr His Gly Asn Gly Gln Ser Tyr Arg Gly Thr Phe
 1 5 10 15

Ser Thr Thr Val Thr Gly Arg Thr Cys Gln Ser Trp Ser Ser Met Thr
 20 25 30

Pro His Arg His Gln Arg Thr Pro Glu Asn Tyr Pro Asn Asp Gly Leu
 5 35 40 45

Thr Met Asn Tyr Cys Arg Asn Pro Asp Ala Asp Thr Gly Pro Trp Cys
 50 55 60

10 Phe Thr Thr Asp Pro Ser Ile Arg Trp Glu Tyr Cys Asn Leu Thr Arg
 65 70 75 80

Cys Ser Asp Thr Glu Gly Thr Val Val
 85

15

<210> 7
 <211> 258
 <212> DNA
 20 <213> Homo sapiens

<400> 7
 gaacaggact gcatgtttgg gaatgggaaa ggataccggg gcaagaaggc aaccactgtt 60
 25 actgggacgc catgccagga atgggctgcc caggagcccc atagacacag cacgttcatt 120
 ccagggacaa ataaatgggc aggtctggaa aaaaattact gccgtaacct tgatggtgac 180
 atcaatggtc cctggtgcta cacaatgaat ccaagaaaac tttttgacta ctgtgatatc 240
 30 cctctctgtg catcctct 258

<210> 8
 35 <211> 86
 <212> PRT
 <213> Homo sapiens

<400> 8
Glu Gln Asp Cys Met Phe Gly Asn Gly Lys Gly Tyr Arg Gly Lys Lys
1 5 10 15
5
Ala Thr Thr Val Thr Gly Thr Pro Cys Gln Glu Trp Ala Ala Gln Glu
20 25 30
Pro His Arg His Ser Thr Phe Ile Pro Gly Thr Asn Lys Trp Ala Gly
10 35 40 45
Leu Glu Lys Asn Tyr Cys Arg Asn Pro Asp Gly Asp Ile Asn Gly Pro
50 55 60
15 Trp Cys Tyr Thr Met Asn Pro Arg Lys Leu Phe Asp Tyr Cys Asp Ile
65 70 75 80
Pro Leu Cys Ala Ser Ser
85
20
<210> 9
<211> 29
<212> DNA
25 <213> Artificial Sequence
<220>
<223> single stranded oligonucleotide
30 <400> 9
tccatatgaa aagccctgtg gtccaggat 29

<210> 10
35 <211> 33
<212> DNA
<213> Artificial Sequence

<220>

<223> single stranded oligonucleotide

5 <400> 10

cagtcctat ggtccgccag tgctacca gca

33

<210> 11

10 <211> 31

<212> DNA

<213> Artificial Sequence

<220>

15 <223> single stranded oligonucleotide

<400> 11

ggaattccat atggaacagg actgcatgtt t

31

20

<210> 12

<211> 26

<212> DNA

<213> Artificial Sequence

25

<220>

<223> single stranded oligonucleotide

<400> 12

30 cgggatcctt aacctgattc tgtttc

26

<210> 13

<211> 26

35 <212> DNA

<213> Artificial Sequence

<220>

<223> single stranded oligonucleotide

<400> 13

5 cgggatcctt agaccacagt cccttc

26

<210> 14

<211> 23

10 <212> DNA

<213> Artificial Sequence

<220>

<223> single stranded oligonucleotide

15

<400> 14

cgggatcctt aagaggatgc aca

23